Pasar al contenido principal

Amplificación de la polimerasa en combinación con un array electroquímico de flujo lateral en papel para la cuantificación de las resistencias a antibióticos (PAPYRUs).

PLEC2021-007972

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i en Líneas Estratégicas
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario PAPERDROP DIAGNOSTICS, SOCIEDAD LIMITADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Toward next generation lateral flow assays: Integration of nanomaterials

  • Sena-Torralba, Amadeo
  • Álvarez-Diduk, Ruslan
  • Parolo, Claudio
  • Piper, Andrew
  • Merkoçi, Arben
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we highlight the strategies that can synergistically solve the limitations of current LFAs and that have proven commercial feasibility. Finally, we discuss the barriers toward commercialization and the next generation of LFAs., We acknowledge financial support to the project AC21_2/00044 (GLEBIOASSAY), funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union, MICROBPREDICT project (European Union Horizon 2020 research and innovation program under grant agreement 825694), and Graphene Flagship Core 3 (European Union Horizon 2020 research and innovation program under grant agreement 881603). ICN2 is funded by CERCA programme, Generalitat de Catalunya. Grant SEV-2017-0706 is funded by MCIN/AEI/10.13039/501100011033. The authors also acknowledge the Project PID2021-124795NB-I00 funded by MCIN/AEI/10.13039/501100011033/and FEDER Una manera de hacer Europa and the project PAPYRUS: Grant PLEC2021-007972 funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”. The authors acknowledge Consejo Superior de Investigaciones Científicas (CSIC) for the project “COVID19-122” granted in the call “Nuevas ayudas extraordinarias a proyectos de investigación en el marco de las medidas urgentes extraordinarias para hacerfrente al impacto económico y social del COVID-19” (Ayudas CSIC-COVID-19). A.S.-T. acknowledges MINECO for the Juan de la Cierva Formación fellowship (FJC2020-043927-I). C.P. acknowledges the Marie Skłodowska-Curie Actions Individual Fellowship; this project received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 795635. C.P. (ISGlobal) also acknowledges support from the Spanish Ministry of Science and Innovation** and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019−2023” Program (CEX2018-000806-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture

  • Monge Olivares, Laura
  • López-Hernández, Inmaculada
  • Fernández-Cuenca, Felipe
  • Pascual, Álvaro
  • López-Cerero, Lorena
[Objectives] Carbapenemase-producing Gram-negative bacteria represent a major clinical challenge. Rapid detection and characterization of carbapenemase group is essential for guiding therapy and for infection control. We evaluated the performance of Certest ResisCheck® Carbapenemases, a novel lateral flow immunoassay (LFIA), for detecting the main carbapenemase groups from bacterial culture., [Materials and methods] A multicentre collection of 351 well-characterized clinical Gram-negative isolates, studied by whole-genome sequencing, was tested using this assay. 57 KPC, 53 NDM, 63 VIM, 68 OXA-48-like, 64 IMP and 100 carbapenem resistant non-carbapenemase producers were included., [Results] The LFIA showed an overall sensitivity of 96.4% and specificity of 100%. The positive predictive value (PPV) was 100%, and the negative predictive value (NPV) was 91.7%. No false-positives or cross-reactions with extended-spectrum β-lactamases (ESBLs) or cephalosporinases were observed either with isolates harbouring multiple carbapenemases. Detection rates for IMP and NDM variants reached 100%. Sensitivity for KPC, OXA-like and VIM was slightly lower (93.0%, 95.6% and 96.8%, respectively). Nine false-negative results were observed: KPC-31 (n = 4), VIM-63 (n = 2) and OXA-1054-producing (n = 3) isolates. Increasing the bacterial inoculum managed to obtain a positive result for KPC-31 and VIM-63, but OXA-1054 remained undetected., [Conclusions] Certest ResisCheck® Carbapenemases is a rapid, accurate, and reliable tool for detecting carbapenemases in clinical settings. While some rare variants may escape detection, its strong performance across diverse bacterial species supports its use as part of routine diagnostics to guide timely antimicrobial therapy and control the spread of resistance., This work was funded by MICIU/AEI/10.13039/501100011033/FEDER and European Union ‘NextGenerationEU’/PRTR’ (PLEC2021-007972), and by MICIU/AEI/10.13039/501100011033/FEDER, European Union and Ministry of Science, Innovation and Universities, the Agency and the European Regional Development Fund (PLEC2024-011123)., Peer reviewed